Prostaglandin A2
Based on 1 Customer Validation
Prostaglandin A2 (PGA2) is a Cyclopentenone prostaglandin. Prostaglandin A2 induces Caspase-dependent Apoptosis, activates p53. Prostaglandin A2 activates ERK2 and JNK1/SAPK. Prostaglandin A2 shows antiviral activity against HSV-1. Prostaglandin A2 has anti-tumor effects. Prostaglandin A2 can be used for the research of colorectal cancer, colorectal carcinoma, breast carcinoma, and herpetic keratitis.
For research use only. We do not sell to patients.
- Purity : 99.9%
- CAS No.: 13345-50-1
- Formula: C20H30O4
- Molecular Weight:334.45
-
Storage:
Solution, -20°C, protect from light, 2 years
All Caspase Isoforms
More
Biological Activity
Description
|
JNK1 |
ERK2 |
PARP-1 |
Caspase 3 |
HSV-1 |
In Vitro
Prostaglandin A2 (5-15 μg/mL; 12 h) induces caspase-dependent apoptosis in HCT116 (wild-type p53) cells, but exerts no such effect in HCT116 p53-/- cells[1].
Prostaglandin A2 (36 μM; 48 h) induces growth arrest in MCF-7 human breast cancer cells, and triggers apoptotic death in RKOneo and RKOE6 human colorectal cancer cells[2].
Prostaglandin A2 (36 μM; 30-120 min) potently activates ERK2 and JNK1/SAPK kinases in MCF-7 cells, but exerts no such effect in RKO cells[2].
Prostaglandin A2 inhibits the replication of HSV-1 strain McKrae in rabbit stromal cells, with an ED50 of 1.2 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human colorectal HCT116 (wild-type p53) cells, HCT116 p53-/- cells
-
Concentration:5, 10, 15 μg/mL
-
Incubation Time:12 h
-
Result:Induced cleavage of PARP1 and caspase-3 in HCT116 cells in a dose-dependent manner, but not in HCT116 p53-/- cells.
Increased p53 protein levels and p53 phosphorylation at Ser-15 in HCT116 cells in a dose-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:New Zealand White rabbits (2.3 to 2.7 kg, free of preexisting corneal defects)[3]
-
Dosage:0.5 mg/mL; 1.0 mg/mL; 2.0 mg/mL
-
Administration:topical eyedrops; five doses per day every 2 hours; days 3 to 7 post-infection
-
Result:Showed only one significant epithelial lesion score reduction vs.
placebo at a single dose and time point; overall, epithelial disease did not respond in a dose-dependent manner.
Recorded mean lesion scores on day 8 post-infection of 1.7 (1 mg/mL) and 2.1 (2 mg/mL).
Observed no significant differences in corneal thickness between treated and placebo groups at peak stromal involvement (12 to 14 days post-infection), with mean corneal thicknesses at day 12 post-infection of 473 ± 23 μm (0.5 mg/mL), 582 ± 76 μm (1.0 mg/mL), and 541 ± 42 μm (2.0 mg/mL).
Detected significantly higher anterior chamber flare scores in treated groups vs.
placebo in a dose-dependent manner, with mean flare scores after 1 day of therapy of 0.44 (0.5 mg/mL), 0.88 (1 mg/mL), and 1.03 (2 mg/mL).
Caused worse long-term sequelae in treated rabbits, with mean corneal thickness at 67 days post-infection of 569 ± 120 μm (1 mg/mL) and 694 ± 124 μm (2 mg/mL) vs.
480 ± 70 μm for placebo, and 14 of 28 treated eyes developing necrotizing stromal keratitis vs.
3 of 10 placebo eyes.
Observed no differences in virus recovery from trigeminal ganglia or corneas between treated and placebo groups, with 15 of 18 trigeminal ganglia from treated rabbits yielding infectious virus upon cocultivation, and 4 of 18 or 5 of 12 corneas from treated rabbits yielding infectious virus.
Chemical Information
-
CAS No. 13345-50-1
-
Appearance Liquid
-
Molecular Weight 334.45
-
Formula C20H30O4
-
Color Colorless to light yellow
-
SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C(C=C1)=O)C/C=C\CCCC(O)=O
-
Synonyms
PGA2; Medullin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Solution, -20°C, protect from light, 2 years
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee SB, et al. Induction of p53-Dependent Apoptosis by Prostaglandin A2. Biomolecules. 2020;10(3):492. Published 2020 Mar 24. [Content Brief]
[2]. Gorospe M, et al. Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol Cell Biol. 1996 Dec;16(12):6654-60. [Content Brief]
[3]. O'Brien WJ, et al. Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis. Antimicrob Agents Chemother. 1996;40(10):2327-2331. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Prostaglandin A2
- 13345-50-1
- PGA2
- Medullin
- Prostaglandin A 2
- Prostaglandin A-2
- PGA 2
- PGA-2
- Apoptosis
- Caspase
- PARP
- ERK
- MDM-2/p53
- JNK
- HSV
- p53
- cyclin-dependent kinases
- DNA-activated protein kinase
- poly(ADP-ribose) polymerase 1
- histone H2AX
- DR5
- extracellular signal-regulated kinase
- c-Jun terminal kinase 1/stress-activated protein kinase
- caspase-3
- colorectal cancer
- Inhibitor
- inhibitor
- inhibit